Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma.
| Autor: | Akbari, Abolfazl, Amanpour, Saeid, Muhammadnejad, Samad, Hossein Ghahremani, Mohammad, Hamidollah Ghaffari, Seyed, Reza Dehpour, Ahmad, Reza Mobini, Gholam, Shidfar, Fatemeh, Abastabar, Mahdi, Khoshzaban, Ahad, Faghihloo, Ebrahim, Karimi, Abbas, Heidari, Mansour |
|---|---|
| Předmět: |
STAINS & staining (Microscopy)
IMMUNOHISTOCHEMISTRY ADENOCARCINOMA ANALYSIS of variance ANIMAL experimentation BIOLOGICAL assay BIOPHYSICS CELL culture CELLULAR signal transduction COLON tumors ENZYME-linked immunosorbent assay GROWTH factors HISTOLOGICAL techniques RESEARCH methodology MICE STATISTICS T-test (Statistics) DATA analysis PROTEIN kinase inhibitors DESCRIPTIVE statistics IN vitro studies |
| Zdroj: | DARU: Journal of Pharmaceutical Sciences; 2014, Vol. 22, p47-66, 20p, 5 Color Photographs, 1 Chart, 1 Graph |
| Abstrakt: | Background: Transforming growth factor-β (TGF-β) pathway is involved in primary tumor progression and in promoting metastasis in a considerable proportion of human cancers such as colorectal cancer (CRC). Therefore, blockage of TGF-β pathway signaling via an inhibitor could be a valuable tool in CRC treatment. To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells. In this work, in vitro cell proliferation was studied by Methyl thiazolyl tetrazolium (MTT) and Bromo-2′-deoxyuridine (BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and eosin, and Ki-67 and CD34 markers are staining, respectively. Methods: To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells. In this work, in vitro cell proliferation was studied by Methyl thiazolyl tetrazolium (MTT) and Bromo-2′-deoxyuridine (BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and eosin, and Ki-67 and CD34 markers are staining, respectively. Results: Our results showed no significant reduction in cell proliferation and vessel formation (170 ± 70 and 165 ± 70, P > 0.05) in treated SW-48 cells with SD-208 compared to controls. Conclusion: Our data suggested that SD-208 could not significantly reduce tumor growth and angiogenesis in human colorectal cancer model at least using SW-48 cells. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|